Less bleeding seen with rivaroxaban in large lung clot study

03/27/2012 | Reuters

The anticoagulant rivaroxaban is safer than and works as well as standard dual therapy for blood clots of the lung, according to a 4,833-patient study presented at a cardiology meeting. A lower percentage of patients taking rivaroxaban experienced major and minor bleeding compared with those who took the combination therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC